

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**SCHEDULE TO**

**TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1)  
OF THE SECURITIES EXCHANGE ACT OF 1934  
(Amendment No. 8)**

---

**IDENIX PHARMACEUTICALS, INC.**

(Name of Subject Company (Issuer))

**IMPERIAL BLUE CORPORATION**

(Offeror)

a wholly owned subsidiary of

**MERCK & CO., INC.**

(Offeror)

(Names of Filing Persons (identifying status as offeror, issuer or other person))

**COMMON STOCK, PAR VALUE \$0.001 PER SHARE**

(Title of Class of Securities)

**45166R204**

(CUSIP Number of Class of Securities)

**Geralyn S. Ritter**

**Senior Vice President, Global Public Policy and Corporate Responsibility,  
Secretary and Assistant General Counsel**

**Merck & Co., Inc.**

**One Merck Drive, P.O. Box 100,  
Whitehouse Station, NJ 08889-0100  
(908) 423-1000**

(Name, address, and telephone numbers of person authorized to receive notices and communications on behalf of filing persons)

*Copies to:*

**James Modlin**

**David Schwartz**

**Hughes Hubbard & Reed LLP**

**One Battery Park Plaza**

**New York, NY 10004**

**(212) 837-6000**

---

### CALCULATION OF FILING FEE

Transaction Valuation*	Amount of Filing Fee**
\$3,852,404,200	\$496,189.66

- \* Calculated solely for purposes of determining the filing fee. The calculation of the transaction value is determined by adding the sum of (i) 150,856,104 shares of common stock, par value \$0.001 per share, of Idenix Pharmaceuticals, Inc. ("Idenix") multiplied by the offer price of \$24.50 per share and (ii) the net offer price for 8,794,634 shares issuable pursuant to outstanding options with an exercise price less than \$24.50 per share (which is calculated by multiplying the number of shares underlying such outstanding options by an amount equal to \$24.50 minus such applicable exercise price). The calculation of the filing fee is based on information provided by Idenix as of June 8, 2014.
- \*\* The filing fee was calculated in accordance with Rule 0-11 under the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory No. 1 for Fiscal Year 2014, issued August 30, 2013, by multiplying the transaction valuation by 0.00012880.

- Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

Amount Previously Paid: \$496,189.66  
Form of Registration No.: Schedule TO-T

Filing Party: Merck & Co., Inc.  
Date Filed: June 20, 2014

- Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

- Third-party tender offer subject to Rule 14d-1.
- Issuer tender offer subject to Rule 13e-4.
- Going-private transaction subject to Rule 13e-3.
- Amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer.

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

- Rule 13e-4(i) (Cross-Border Issuer Tender Offer)
- Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

This Amendment No. 8 (this “Amendment”) amends and supplements the Tender Offer Statement on Schedule TO, originally filed with the Securities and Exchange Commission (the “SEC”) on June 20, 2014 (together with any amendments and supplements thereto, including Amendment No. 1 filed with the SEC on June 26, 2014, Amendment No. 2 filed with the SEC on June 27, 2014, Amendment No. 3 filed with the SEC on July 3, 2014, Amendment No. 4 filed with the SEC on July 11, 2014, Amendment No. 5 filed with the SEC on July 21, 2014, Amendment No. 6 filed with the SEC on July 24, 2014, Amendment No. 7 filed with the SEC on August 5, 2014 and this Amendment, the “Schedule TO”), which relates to the tender offer by Imperial Blue Corporation, a Delaware corporation (“Purchaser”) and a wholly-owned subsidiary of Merck & Co., Inc., a New Jersey corporation (“Parent”), for all of the outstanding shares of common stock, par value \$0.001 per share (“Shares”), of Idenix Pharmaceuticals, Inc., a Delaware corporation (“Idenix”), at a price of \$24.50 per share, net to the seller in cash, without interest, but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated June 20, 2014 (as amended, the “Offer to Purchase”), a copy of which is attached as Exhibit (a)(1)(A), and in the related letter of transmittal (the “Letter of Transmittal”), a copy of which is attached as Exhibit (a)(1)(B), which, as each may be amended or supplemented from time to time, collectively constitute the “Offer.” This Amendment is being filed on behalf of Parent and the Purchaser. Capitalized terms used and not otherwise defined in this Amendment have the meanings set forth in the Offer to Purchase.

All the information set forth in the Offer to Purchase, to the extent incorporated by reference therein, is hereby amended and supplemented as set forth below.

#### **Item 11. ADDITIONAL INFORMATION**

Item 11 of the Schedule TO is hereby amended and supplemented by adding the following text thereto:

“On August 5, 2014, Purchaser merged with and into Idenix, without a meeting of the stockholders of Idenix in accordance with Section 251(h) of the General Corporation Law of the State of Delaware, with Idenix continuing as the surviving corporation and thereby becoming a wholly-owned subsidiary of Parent. Each outstanding Share (other than Shares held (i) in the treasury of Idenix or by Parent, Purchaser or any of Parent’s other subsidiaries, which Shares were canceled and ceased to exist or (ii) by stockholders who validly exercised appraisal rights under Delaware law with respect to such Shares) were automatically canceled and converted into the right to receive \$24.50 per Share, without interest, but subject to any required withholding of taxes. Idenix ceased to be a publicly traded company on NASDAQ at the close of market on August 5, 2014.”

---

**SIGNATURES**

After due inquiry and to the best of their knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: August 6, 2014

**IMPERIAL BLUE CORPORATION**

By: /s/ Sunil A. Patel  
Name: Sunil A. Patel  
Title: Vice President

**MERCK & CO., INC.**

By: /s/ Katie Fedosz  
Name: Katie Fedosz  
Title: Senior Assistant Secretary